# Pentoxifylline Effect in Patients With Diabetic Nephropathy.(PENFOSIDINE STUDY)

Study · id `cardio:ct-nct03664414` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03664414](<https://clinicaltrials.gov/study/NCT03664414>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03664414

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 196 participants.

## Technical summary

Registry record NCT03664414. Randomized; double masking; primary purpose treatment. Start 2018-03-01 (actual); primary completion 2019-07-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 196 participants (planned count; ClinicalTrials.gov record NCT03664414, source copy `cardio:ctgov-nct03664414-2019-02-07`, retrieved 2026-10-26)
- Started: 2018-03-01 (actual) (ClinicalTrials.gov record NCT03664414, source copy `cardio:ctgov-nct03664414-2019-02-07`, retrieved 2026-10-26)
- Primary completion: 2019-07-30 (anticipated) (ClinicalTrials.gov record NCT03664414, source copy `cardio:ctgov-nct03664414-2019-02-07`, retrieved 2026-10-26)
- Completion: 2021-12-31 (anticipated) (ClinicalTrials.gov record NCT03664414, source copy `cardio:ctgov-nct03664414-2019-02-07`, retrieved 2026-10-26)
- Countries: Mexico (ClinicalTrials.gov record NCT03664414, source copy `cardio:ctgov-nct03664414-2019-02-07`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03664414-2019-02-07`, retrieved 2026-10-26)

## The registry's words

- Brief title: Pentoxifylline Effect in Patients With Diabetic Nephropathy.(PENFOSIDINE STUDY)
- Acronym: PENFOSIDINE
- Condition: Chronic Kidney Disease stage3 and 4
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): pentoxifylline
- Lead sponsor: Maria Eugenia Galván Plata
- Lead sponsor class: OTHER\_GOV
- Collaborator: Centro de Investigación Biomédica de Michoacán.
- Collaborator class: UNKNOWN
- Collaborator: Hospital General Regional N° 1 Instituto Mexicano del Seguro Social.
- Collaborator class: UNKNOWN
- Collaborator: Hospital General de Zona N° 83 Instituto Mexicano del Seguro Social.
- Collaborator class: UNKNOWN
- Collaborator: Coordinación Auxiliar Medica de Investigación en Salud. Delegación Michoacán.
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)

## Provenance

Content hash: 06df214253c7e3ba75bab392c8836b5a1a74feaa2663290a8f90018251e60275
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
